Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2026)

Royalty Pharma (RPRX) has 7 years of Other Non-Current Liabilities data on file, last reported at $648.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 3523.87% year-over-year to $648.7 million; the trailing twelve-month figure through Mar 2026 stood at $648.7 million (up 3523.87% YoY), and the FY2025 full-year result was $120.8 million, changed N/A from the prior year.
• Other Non-Current Liabilities grew to $648.7 million in Q1 2026, from $120.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $648.7 million in Q1 2026 to a low of $900000.0 in Q4 2023.
• A 5-year average of $103.9 million and a median of $12.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities plunged 80.55% in 2023 and jumped 8913.23% in 2025, its largest moves.
• Tracing RPRX's Other Non-Current Liabilities over 5 years: stood at $2.5 million in 2022, then slumped by 64.0% to $900000.0 in 2023, then jumped by 520.0% to $5.6 million in 2024, then jumped by 2065.65% to $120.8 million in 2025, then soared by 436.79% to $648.7 million in 2026.
• Business Quant data shows RPRX's Other Non-Current Liabilities at $648.7 million in Q1 2026, $120.8 million in Q4 2025, and $502.9 million in Q3 2025.